LONDON – Bergenbio AS has raised $6 million in a Series B round supported by all the existing investors, providing funding for a number of Phase I trials of its lead product BGB 324, a first-in-class AXL receptor tyrosine kinase inhibitor.
Read More
LONDON – A new study has given hope that it may one day be possible to develop a specific treatment for neuroblastoma, which is a rare type of childhood cancer.
Read More
GHENT, Belgium – Patrik De Haes, CEO of Thrombogenics NV, rang the opening bell – albeit remotely – on the NYSE Euronext Brussels exchange to kick off proceedings at the 2013 Knowledge For Growth meeting at the International Convention Center in Ghent, Belgium, last Thursday.
Read More
LONDON – Nanobiotix SA presented positive safety data from the first clinical study of NBTXR3, a nanoparticle drug that enhances the effects of radiotherapy on tumor cells without damaging healthy tissue, at the American Society of Clinical Oncology (ASCO) meeting in Chicago on Saturday.
Read More
GHENT, Belgium – The pharmaceutical industry has enjoyed 60 years of stability and is now – whether it likes it or not – ripe for disruption. That was the main message Bernard Munos, of InnoThink Center for Research in Biomedical Innovation in Indianapolis, delivered to delegates at a heavily attended keynote at the Knowledge for Growth meeting at the International Convention Center last week.
Read More
• Sinovac Biotech Ltd., of Beijing, said its new drug application for its EV71 vaccine was filed and accepted by the Beijing Drug Administration. Sinovac completed Phase III studies in March showing a 95 percent efficacy rate for the vaccine against hand, foot and mouth disease caused by enterovirus 71.
Read More
